Camostat Mesylate

Phase 3Small molecule

SSeoul National University Hospital

Camostat Mesylate is one of 60 small molecule programs targeting Complication. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

Chronic Kidney DiseaseActive, not recruiting

COVID-19Phase 3

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Camostat Mesylate

SSeoul National University Hospital

Phase 3

1 2

Calciferol

Alnylam Pharmaceuticals

Tricor

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 5

Rayaldee

OOrganon and Co

Preclinical

1 6

Piperacillin/tazobactam

Pfizer

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Orap

Teva

Preclinical

1 9

Aprotinin

Bayer

Preclinical

1 10

Antithrombin-III

Octapharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Chronic Kidney Disease

NCT06794593

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Effect Camostat for Kidney Protection in Chronic Kidney Disease

Recruiting·OOdense University Hospital·Phase 2·NCT06794593·40 enrolled

Complication1 trial

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

Withdrawn·YYale University·Phase 1/2·NCT04435015

Fontan1 trial

Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

Completed·SSeoul National University Hospital·Phase 2·NCT05474664·19 enrolled

COVID-191 trial

CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04608266·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Camostat Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Camostat Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Camostat Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSeoul National University Hospital

Camostat Mesylate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chronic Kidney Disease1 trial

Complication1 trial

Fontan1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News